Q32 Bio sold rights to its phase II complement inhibitor ADX‑097 to Akebia Therapeutics, generating upfront proceeds that materially extend Q32’s cash runway and let the small developer focus resources on its lead alopecia candidate. The transaction includes near‑term payments and potential development and commercial milestones. Akebia said the acquisition strengthens its rare kidney disease pipeline. Company filings and market commentary emphasize the deal’s financing impact for Q32 and strategic fit for Akebia as it builds specialty renal assets.